The Pharmacopoeia of the People's Republic of China is a dynamic and expanding regulatory document that bridges modern chemical medicine and traditional practices. While PDF versions of the text are highly sought after for ease of reference, users should prioritize obtaining the official English translation from the China Medical Science Press to ensure legal accuracy and compliance.
Pharmacopoeia of the People's Republic of China (ChP) is the official drug compendium for China. The current version is the 2020 Edition , which became effective on December 30, 2020. National Medical Products Administration (NMPA)
Because these are copyrighted regulatory documents, full and legitimate PDF versions are typically not available for free direct download from official sources; they usually require a subscription or purchase. However, you can access individual sections or find full versions through the following platforms: Accessing the 2020 English Version Official Information National Medical Products Administration (NMPA)
provides official announcements regarding the publication and implementation of new editions. Commercial Access : Professional services like
offer access to the English version of the 2020 Edition and its latest addendums. Educational Previews
: You can find partial previews or research reviews summarizing the 2020 Edition's changes on ResearchGate PMC (PubMed Central) Older Editions and Community Uploads
Full PDF scans of older editions (2005, 2010, 2015) are often hosted on document-sharing sites, though their completeness and accuracy are not guaranteed: Chinese Pharmacopoeia in English (CP-15) pdf free download
The most current version of the Pharmacopoeia of the People’s Republic of China (ChP) is the 2020 Edition , which became effective on December 30, 2020. An updated 2025 Edition
was recently released in March 2025 and is scheduled for implementation on October 1, 2025. 📘 Content Structure (2020 Edition)
The pharmacopoeia is organized into four main volumes, covering a total of 5,911 monographs. Volume Focus Area Volume I TCM
2,711 monographs on Traditional Chinese Medicine (herbs, oils, prepared slices, and patent medicines). Volume II Chemical Drugs
2,712 monographs on chemical drugs, antibiotics, and active pharmaceutical ingredients (APIs). Volume III Biologics
153 monographs on biological products, including vaccines and recombinant products. Volume IV General Chapters pharmacopoeia of the people 39-s republic of china pdf
361 technical requirements: 38 preparation rules, 281 testing methods, 42 guidelines, and 335 excipient monographs. ✨ Key Features & Updates
Safety Enhancements: Includes stricter limits for heavy metals, pesticide residues, and mycotoxins in TCM.
Advanced Testing: Introduces modern techniques like DNA sequencing, PCR, and Raman spectroscopy for drug identification.
International Alignment: Significant efforts were made to harmonize technical requirements with ICH guidelines (e.g., Q1A stability and Q2 validation).
Excipients focus: Increased monographs for pharmaceutical excipients to ensure the quality of final drug formulations. 📎 Accessing the PDF
Chinese Pharmacopoeia 2020 - English ed. issued ... - Cisema
Finding a single PDF containing the entire Pharmacopoeia of the People's Republic of China (ChP) is generally not possible through legal or open-access channels, as it is a copyrighted, multi-volume government publication typically sold by the China Medical Science Press.
However, below is a comprehensive research guide and "white paper" style overview regarding the 2020 Edition (Current), including its structure, how to access it, and what critical information a researcher needs to know.
The official language of the ChP is Simplified Chinese. However, because China is a major exporter of Active Pharmaceutical Ingredients (APIs), the Pharmacopoeia Commission publishes an official English translation.
If you search for "Pharmacopoeia of the People's Republic of China PDF" in English, you must verify:
Pro Tip: For regulatory filing with the FDA or EMA, you must cite the English version. However, if there is a discrepancy between the English PDF and the Chinese hardcopy, the Chinese version prevails by law.
The Pharmacopoeia of the People's Republic of China, commonly abbreviated as ChP (or Zhongguo Yaodian), is the official compendium of drugs, excipients, and traditional medicines. It is issued by the Chinese Pharmacopoeia Commission (ChPC) under the supervision of the National Medical Products Administration (NMPA). The Pharmacopoeia of the People's Republic of China
The pharmacopoeia serves as the binding legal standard for:
If a pharmaceutical product is sold in mainland China, its quality must conform to the standards set in the latest edition of the ChP.
You might find a PDF of ChP 2005 or 2010. While useful for historical research, using these for current drug registration with the NMPA will result in automatic rejection.
Short answer: No.
Long answer: While the allure of a free Pharmacopoeia of the People's Republic of China PDF is strong, the risks of using an unauthorized, outdated, or incorrect version far outweigh the cost savings. A single misidentified impurity standard can result in a product recall costing millions.
Instead:
The China Medical Science Press (中国医药科技出版社) holds the copyright.
The Pharmacopoeia of the People's Republic of China is not only important for those within China but also for:
In conclusion, the Pharmacopoeia of the People's Republic of China is a critical document for ensuring drug quality and safety within China and serves as an important reference for international stakeholders in the pharmaceutical industry.
The Pharmacopoeia of the People's Republic of China (ChP) is the official compendium of drug standards for medicinal products in China. Compiled by the Chinese Pharmacopoeia Commission, it serves as a statutory technical specification that all drugs must meet to obtain marketing authorization and be legally manufactured, sold, or used within the country.
The current version, the 2020 Edition (11th Edition), was released on July 2, 2020, and implemented on December 30, 2020. It covers a comprehensive range of Traditional Chinese Medicines (TCM), chemical drugs, biological products, and pharmaceutical excipients. Structure of the 2020 Chinese Pharmacopoeia
The 2020 edition is organized into four volumes, encompassing over 5,900 total monographs, including dedicated volumes for TCM, chemical drugs, biological products, and general technical requirements. The official language of the ChP is Simplified Chinese
Pharmacopoeia of the People's Republic of China 2020 - TSO Shop
History and Development
The first edition of the Chinese Pharmacopoeia was published in 1953, shortly after the founding of the People's Republic of China. The pharmacopoeia was compiled by a team of experts from the Ministry of Health, the Chinese Academy of Sciences, and other relevant institutions. The initial edition was a 1,200-page book that included 850 monographs on medicinal substances, 450 formulas, and 100 biological products.
Over the years, the pharmacopoeia has undergone numerous revisions, with new editions published in 1963, 1977, 1985, 1990, 1995, 2000, 2005, and 2010. The current edition, the 11th edition, was published in 2020.
Significance and Content
The Chinese Pharmacopoeia is a vital reference for:
The pharmacopoeia contains a wide range of information, including:
PDF Version
The Chinese Pharmacopoeia is available in print and digital formats, including a PDF version. The PDF version offers several advantages, including:
The PDF version of the Chinese Pharmacopoeia is available from various sources, including:
Conclusion
The Pharmacopoeia of the People's Republic of China is a critical publication that has played a vital role in ensuring the quality and safety of medicines in China. The PDF version offers a convenient and accessible way for users to consult the pharmacopoeia, facilitating the evaluation, approval, and use of medicines in China and beyond.